Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) Net Margin (2020 - 2024)

Fulcrum Therapeutics (FULC) has disclosed Net Margin for 5 consecutive years, with 69.26% as the latest value for Q2 2024.

  • On a quarterly basis, Net Margin changed N/A to 69.26% in Q2 2024 year-over-year; TTM through Mar 2025 was 0.64%, a 202673.0% increase, with the full-year FY2024 number at 12.16%, up 345790.0% from a year prior.
  • Net Margin was 69.26% for Q2 2024 at Fulcrum Therapeutics, up from 3164.3% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 69.26% in Q2 2024 to a low of 9471.19% in Q1 2023.
  • A 5-year average of 1673.41% and a median of 784.25% in 2020 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: soared 210531bps in 2021, then plummeted -847088bps in 2023.
  • Fulcrum Therapeutics' Net Margin stood at 419.41% in 2020, then fell by -11bps to 464.29% in 2021, then tumbled by -290bps to 1810.31% in 2022, then plummeted by -75bps to 3164.3% in 2023, then skyrocketed by 102bps to 69.26% in 2024.
  • Per Business Quant, the three most recent readings for FULC's Net Margin are 69.26% (Q2 2024), 3164.3% (Q3 2023), and 9471.19% (Q1 2023).